SIERRA ONCOLOGY, INC.

(SRRA)
  Report
Delayed Nasdaq  -  04:00 2022-06-29 pm EDT
54.97 USD   +0.02%
06/29Sierra Oncology Shareholders Approve Acquisition by GSK
MT
06/29SIERRA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)
AQ
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) added to Russell Small Cap Comp Growth Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/23/2022 06/24/2022 06/27/2022 06/28/2022 06/29/2022 Date
54.95(c) 54.91(c) 54.95(c) 54.96(c) 54.97(c) Last
184 731 2 379 177 326 717 281 516 594 648 Volume
+0.02% -0.07% +0.07% +0.02% +0.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -98,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -11,5x
Yield 2022 -
Sales 2023 28,7 M - -
Net income 2023 -88,2 M - -
Net Debt 2023 - - -
P/E ratio 2023 -14,2x
Yield 2023 -
Capitalization 1 342 M 1 342 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 46,8x
Nbr of Employees 109
Free-Float 91,4%
More Financials
Company
Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a... 
More about the company
Ratings of Sierra Oncology, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about SIERRA ONCOLOGY, INC.
06/29Sierra Oncology Shareholders Approve Acquisition by GSK
MT
06/29SIERRA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders, Other Events ..
AQ
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) added to Russell Small Cap Comp Growth Index
CI
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) dropped from Russell Microcap Value Index
CI
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) added to Russell 3000 Growth Index
CI
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) added to Russell 2000 Dynamic Index
CI
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) added to Russell 2000 Index
CI
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) added to Russell 2000 Growth Index
CI
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) added to Russell 3000E Index
CI
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) dropped from Russell 3000E Value Index
CI
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) added to Russell 3000E Growth Index
CI
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) added to Russell 3000 Index
CI
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) added to Russell Small Cap Completeness Index
CI
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) added to Russell 2500 Growth Index
CI
06/24SIERRA ONCOLOGY, INC.(NASDAQGM : SRRA) added to Russell 2500 Index
CI
More news
News in other languages on SIERRA ONCOLOGY, INC.
06/29Les actionnaires de Sierra Oncology approuvent l'acquisition par GSK
06/17Sierra Oncology, Inc. annonce le dépôt d'une demande de nouveau médicament pour le Mome..
06/01Pfizer sortira des soins grand public de GSK après la scission
06/01Pfizer vendra sa participation dans le secteur des produits de santé grand public de GS..
05/31GSK PLC : GSK compra Affinivax por 3.300 millones de dólares
More news
Analyst Recommendations on SIERRA ONCOLOGY, INC.
More recommendations
Chart SIERRA ONCOLOGY, INC.
Duration : Period :
Sierra Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SIERRA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 54,97 $
Average target price 55,00 $
Spread / Average Target 0,05%
EPS Revisions
Managers and Directors
Stephen George Dilly President, Chief Executive Officer & Director
Sukhi Jagpal Chief Financial Officer
Robert E. Pelzer Chairman
Barbara Klencke Chief Medical & Development Officer
William D. Turner Chief Regulatory & Technical Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
SIERRA ONCOLOGY, INC.152.81%1 342
GILEAD SCIENCES, INC.-13.95%78 031
VERTEX PHARMACEUTICALS27.66%70 632
REGENERON PHARMACEUTICALS, INC.-5.37%64 046
WUXI APPTEC CO., LTD.-14.46%44 352
BIONTECH SE-45.76%33 979